.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,318,709

« Back to Dashboard

Details for Patent: 8,318,709

Title:Combination of azelastine and mometasone for nasal administration
Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
Inventor(s): Lulla; Amar (Mumbai, IN), Malhotra; Geena (Mumbai, IN)
Assignee: Cipla Limited (Mumbai, IN)
Filing Date:Jul 23, 2009
Application Number:12/508,388
Claims:1. A pharmaceutical formulation comprising: azelastine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable ester of mometasone, wherein said pharmaceutical formulation is in a dosage form suitable for nasal administration.

2. The pharmaceutical formulation according to claim 1, wherein said pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

3. The pharmaceutical formulation according to claim 1, wherein said pharmaceutically acceptable ester of mometasone is mometasone furoate or mometasone furoate monohydrate.

4. The pharmaceutical formulation according to claim 1, which contains from 0.001 to 1% (weight/weight of the formulation) of said azelastine, or a pharmaceutically acceptable salt thereof, and from 0.5% to 1.5% (weight/weight of the formulation) of said pharmaceutically acceptable ester of mometasone.

5. The pharmaceutical formulation according to claim 1, wherein said pharmaceutically acceptable salt of azelastine is azelastine hydrochloride and said pharmaceutically acceptable ester of mometasone is mometasone furoate.

6. The pharmaceutical formulation according to claim 1, wherein said pharmaceutically acceptable salt of azelastine is azelastine hydrochloride and said pharmaceutically acceptable ester of mometasone is mometasone furoate monohydrate.

7. The pharmaceutical formulation according to claim 1, which is an aqueous suspension or solution.

8. The pharmaceutical formulation according to claim 1, wherein said dosage form suitable for nasal administration comprises nasal drops or a nasal spray.

9. The pharmaceutical formulation according to claim 1, wherein said dosage form suitable for nasal administration comprises nasal drops.

10. The pharmaceutical formulation according to claim 1, wherein said dosage form suitable for nasal administration comprises nasal spray.

11. The pharmaceutical formulation according to claim 1, further comprising at least one additive selected from the group consisting of a buffer, a preservative, a suspending agent, a thickening agent, a surfactant, an isotonic agent, and combinations thereof.

12. The pharmaceutical formulation according to claim 11, wherein the buffer, when present, maintains the pH of the aqueous phase from 3 to 7.

13. The pharmaceutical formulation according to claim 11, wherein the surfactant, when present, comprises a polysorbate, poloxamer or combinations thereof.

14. The pharmaceutical formulation according to claim 11, wherein the isotonic agent, when present, comprises sodium chloride, saccharose, glucose, glycerine, sorbitol, 1,2-propylene glycol, or combinations thereof.

15. The pharmaceutical formulation according to claim 11, wherein said preservative, when present, comprises edetic acid and its alkali salts, lower alkyl p-hydroxybenzoates, chlorhexidine, phenyl mercury borate, benzoic acid or a salt, a quaternary ammonium compound, sorbic acid or a salt thereof, or combinations thereof.

16. The pharmaceutical formulation according to claim 11, wherein the suspending agent or thickening agent, when present, comprises cellulose derivatives, gelatin, polyvinylpyrrolidone, tragacanth, alginic acid, polyvinyl alcohol, polyacrylic acid, pectin, or combinations thereof.

17. The pharmaceutical formulation according to claim 11, wherein the buffer, when present, comprises a citric acid-citrate buffer.

18. A pharmaceutical product comprising (i) azelastine, or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable ester of mometasone, as a combined preparation for use in medicine as an antihistamine and anti-inflammatory agent, said (i) azelastine, or a pharmaceutically acceptable salt thereof and (ii) said pharmaceutically acceptable ester of mometasone being in a dosage form suitable for nasal administration.

19. The pharmaceutical product according to claim 18, wherein said pharmaceutically acceptable salt of azelastine is azelastine hydrochloride and said pharmaceutically acceptable ester of mometasone is mometasone furoate.

20. The pharmaceutical product according to claim 18, wherein said pharmaceutically acceptable salt of azelastine is azelastine hydrochloride and said pharmaceutically acceptable ester of mometasone is mometasone furoate monohydrate.

21. The pharmaceutical product according to claim 18, wherein said product is formulated for use as a nasal spray in the treatment of seasonal allergic rhinitis or perennial allergic rhinitis.

22. The pharmaceutical product according to claim 18, wherein said product is formulated for use as nasal drops in the treatment of seasonal allergic conjunctivitis or perennial allergic conjunctivitis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc